{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:10:08Z","timestamp":1791223808490,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.clml.2014.02.003","type":"journal-article","created":{"date-parts":[[2014,2,15]],"date-time":"2014-02-15T21:31:09Z","timestamp":1392499869000},"page":"424-430.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Induction Bortezomib in AL Amyloidosis Followed By High Dose Melphalan and Autologous Stem Cell Transplantation: A Single Institution Retrospective Study"],"prefix":"10.1016","volume":"14","author":[{"given":"Emma C.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Heitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Dibb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnoush","family":"Abar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Kovacsovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galit","family":"Perez-Avraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Stentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Frires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Dibb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.02.003_bib1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/ajh.21934","article-title":"Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Gertz","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2014.02.003_bib2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.02.003_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4065\/mcp.2010.0480","article-title":"Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score","volume":"86","author":"Kumar","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2014.02.003_bib4","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.1002\/cncr.27660","article-title":"Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis","volume":"118","author":"Cordes","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.02.003_bib5","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1182\/blood-2007-07-099481","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation","volume":"110","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.02.003_bib6","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3109\/10428194.2010.524329","article-title":"Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report","volume":"51","author":"Gertz","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.02.003_bib7","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.02.003_bib8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2012.170","article-title":"Refinement in patient selection to reduce treatment-related mortality from SCT in amyloidosis","volume":"48","author":"Gertz","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2014.02.003_bib9","first-page":"620","article-title":"Treatment of immunoglobulin light chain (primary or AL) amyloidosis","volume":"25","author":"Gertz","year":"2011","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clml.2014.02.003_bib10","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/sj.bmt.1704691","article-title":"Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate","volume":"34","author":"Gertz","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2014.02.003_bib11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2141.2007.06783.x","article-title":"Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone\u00a0+\/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial","volume":"139","author":"Cohen","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.02.003_bib12","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2004-01-0390","article-title":"Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"104","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.02.003_bib13","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1182\/blood-2003-12-4192","article-title":"Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study","volume":"103","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.02.003_bib14","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3324\/haematol.11413","article-title":"Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response","volume":"92","author":"Gertz","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.02.003_bib15","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/leu.2012.274","article-title":"Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis","volume":"27","author":"Landau","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.02.003_bib16","unstructured":"American Society of Hematology. Atlanta, Georgia, Dec 8-11, 2012. Blood (ASH Annual Meeting Abstracts) 2012; 120:Abstract 2019."},{"key":"10.1016\/j.clml.2014.02.003_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2014.02.003_bib18","first-page":"48","article-title":"Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion","volume":"17","author":"Gertz","year":"2010","journal-title":"Amyloid"},{"key":"10.1016\/j.clml.2014.02.003_bib19","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.02.003_bib20","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.02.003_bib21","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/01.CIR.0000025242.79963.4C","article-title":"B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study","volume":"106","author":"McCullough","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.clml.2014.02.003_bib22","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.02.003_bib23","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/bmt.2010.234","article-title":"Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006","volume":"46","author":"Gertz","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2014.02.003_bib24","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjh.12673","article-title":"Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution","volume":"164","author":"Jimenez-Zepeda","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.02.003_bib25","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1200\/JCO.2008.21.1060","article-title":"Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials","volume":"27","author":"Harousseau","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.02.003_bib26","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.2009.25.4250","article-title":"Importance of achieving a complete response in multiple myeloma, and the impact of novel agents","volume":"28","author":"Chanan-Khan","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.02.003_bib27","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2011-02-334227","article-title":"Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1\/2 study","volume":"118","author":"Reece","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.02.003_bib28","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.02.003_bib29","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1704346","article-title":"High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial","volume":"33","author":"Sanchorawala","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2014.02.003_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12185-008-0139-7","article-title":"Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib","volume":"88","author":"Hacihanefioglu","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2014.02.003_bib31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1471-2407-6-129","article-title":"Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report","volume":"6","author":"Voortman","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2014.02.003_bib32","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014000457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014000457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:45Z","timestamp":1761870345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014000457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S2152265014000457"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.02.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induction Bortezomib in AL Amyloidosis Followed By High Dose Melphalan and Autologous Stem Cell Transplantation: A Single Institution Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}